Aplidine treatment of cancers

Details Aplidine treatment of cancers Aplidine treatment of cancers

A - Human Necessities

61

K

A61K 35/56 (2006.01) A61K 31/205 (2006.01) A61K 38/15 (2006.01) A61K 38/17 (2006.01) A61P 35/00 (2006.01)

Patent

CA 2391502

Aplidine demonstrates considerable promise in phase (I) clinical trials for treatment of tumours, and various dosing regimes are given. Tumor reduction has been observed in several tumour types including renal carcinoma, colorectal cancer, lung carcinoid, medullary thyroid carcinomas and melanoma. It has also been found that aplidine has a role in inhibiting angiogenesis, complementing the anti-tumour activity.

L'aplidine s'est avérée très prometteuse lors d'essais cliniques de phase I pour le traitement de tumeurs, et divers schémas posologiques sont décrits. On a observé une réduction de plusieurs types de tumeurs et notamment des carcinomes rénaux, du cancer colorectal, des tumeurs carcinoïdes des poumons, des carcinomes médullaires de la thyroïde et des mélanomes. Il s'est avéré que l'aplidine joue un rôle s'agissant d'inhiber l'angiogenèse, qui s'ajoute à l'activité antitumorale.

Affiliated with

Also associated with

Rating

Aplidine treatment of cancers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aplidine treatment of cancers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aplidine treatment of cancers will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1632720